Skip to content
← Full study record

NCT01248455 · MORE INFO

Limitations, agreements, and source contact

A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma · Source last updated 2019-11-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
Study stopped after the first stage due to lack of patients meeting the defined primary objective (50% decline in M-protein). The study did not continue to the second stage of enrollment due to lack of efficacy as defined by our criteria.
point Of Contact
email
kazandjiandg@mail.nih.gov
organization
National Cancer Institute
phone
301-480-0532
title
Dr. Dickran Kazandijian
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
false
limitations And Caveats
description
Study stopped after the first stage due to lack of patients meeting the defined primary objective (50% decline in M-protein). The study did not continue to the second stage of enrollment due to lack of efficacy as defined by our criteria.
point Of Contact
email
kazandjiandg@mail.nih.gov
organization
National Cancer Institute
phone
301-480-0532
title
Dr. Dickran Kazandijian

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice